Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Florence Joly

Showing results (61-70 of 345) with videos related to

Pageof 35
Sort By:
Bulletin Du Cancer|August 12, 2023
Corinne Jeanne, Isabelle Treilleux, Marie-Aude Le Frère-Belda, et al.
Cancer Treatment Reviews|April 10, 2014
Cognitive dysfunctions in elderly cancer patients: a new challenge for oncologistsMarie Lange, Olivier Rigal, Bénédicte Clarisse, et al.
BMC Medical Genomics|July 4, 2012
Skeletal muscle alterations and exercise performance decrease in erythropoietin-deficient mice: a comparative studyLaurence Mille-Hamard, Veronique L Billat, Elodie Henry, et al.
European Journal of Cancer (Oxford, England : 1990)|June 19, 2016
Long-term quality of life among localised prostate cancer survivors: QALIPRO population-based studyClarisse Kerleau, Anne-Valérie Guizard, Laetitia Daubisse-Marliac, et al.
EJNMMI Research|November 23, 2016
Predictive factors of <sup>18</sup>F-choline PET/CT positivity in patients with prostate cancer recurrence after radiation therapy: is the impact of PSA nadir underestimated?Alison C Johnson, Audrey Emmanuelle Dugué, Marlon Silva, et al.
Bulletin Du Cancer|September 13, 2020
[Long-term occupational situation after cancer: A French registry-based study]Akila Saim, François Gernier, Idlir Licaj, et al.
Nuclear Medicine Communications|December 8, 2015
Pairwise comparison of 18F-FDG and 18F-FCH PET/CT in prostate cancer patients with rising PSA and known or suspected second malignancyNicolas How Kit, Audrey E Dugué, Emmanuel Sevin, et al.
Anti-Cancer Drugs|October 13, 2025
Real-world treatment patterns and survival outcomes in patients with metastatic castration-resistant prostate cancer in France: lessons from the prospective OPALE studyJosephine Papet, Laetitia Augusto-Pelegrin, François Christy, et al.
EJNMMI Research|February 9, 2021
A PSMA-targeted theranostic approach is unlikely to be efficient in serous ovarian cancersNicolas Aide, Laurent Poulain, Nicolas Elie, et al.
Bulletin Du Cancer|October 3, 2008
[Clinical practice guidelines 2008 for the surgical treatment, medical first-line and consolidation treatments of patients with epithelial ovarian cancer--update. According to the methodology of Standards, Options: Recommendations (SOR)]Catherine Lhommé, Philippe Morice, François Planchamp, et al.
Pageof 35

Showing results (61-70 of 345) with videos related to

Sort By:
Pageof 35
Bulletin Du Cancer|August 12, 2023
Corinne Jeanne, Isabelle Treilleux, Marie-Aude Le Frère-Belda, et al.
Cancer Treatment Reviews|April 10, 2014
Cognitive dysfunctions in elderly cancer patients: a new challenge for oncologistsMarie Lange, Olivier Rigal, Bénédicte Clarisse, et al.
BMC Medical Genomics|July 4, 2012
Skeletal muscle alterations and exercise performance decrease in erythropoietin-deficient mice: a comparative studyLaurence Mille-Hamard, Veronique L Billat, Elodie Henry, et al.
European Journal of Cancer (Oxford, England : 1990)|June 19, 2016
Long-term quality of life among localised prostate cancer survivors: QALIPRO population-based studyClarisse Kerleau, Anne-Valérie Guizard, Laetitia Daubisse-Marliac, et al.
EJNMMI Research|November 23, 2016
Predictive factors of <sup>18</sup>F-choline PET/CT positivity in patients with prostate cancer recurrence after radiation therapy: is the impact of PSA nadir underestimated?Alison C Johnson, Audrey Emmanuelle Dugué, Marlon Silva, et al.
Bulletin Du Cancer|September 13, 2020
[Long-term occupational situation after cancer: A French registry-based study]Akila Saim, François Gernier, Idlir Licaj, et al.
Nuclear Medicine Communications|December 8, 2015
Pairwise comparison of 18F-FDG and 18F-FCH PET/CT in prostate cancer patients with rising PSA and known or suspected second malignancyNicolas How Kit, Audrey E Dugué, Emmanuel Sevin, et al.
Anti-Cancer Drugs|October 13, 2025
Real-world treatment patterns and survival outcomes in patients with metastatic castration-resistant prostate cancer in France: lessons from the prospective OPALE studyJosephine Papet, Laetitia Augusto-Pelegrin, François Christy, et al.
EJNMMI Research|February 9, 2021
A PSMA-targeted theranostic approach is unlikely to be efficient in serous ovarian cancersNicolas Aide, Laurent Poulain, Nicolas Elie, et al.
Bulletin Du Cancer|October 3, 2008
[Clinical practice guidelines 2008 for the surgical treatment, medical first-line and consolidation treatments of patients with epithelial ovarian cancer--update. According to the methodology of Standards, Options: Recommendations (SOR)]Catherine Lhommé, Philippe Morice, François Planchamp, et al.
Pageof 35